Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro
暂无分享,去创建一个
M. Petric | S. Richardson | M. Karmali | M. Bitzan | B. Boyd | C. Huang | Mohamed A. Karmali | Martin Bitzan | Susan E. Richardson | Martin Petric
[1] Marsh Derek. The nomenclature of lipids. , 2013, Archives of biochemistry and biophysics.
[2] C. Lingwood,et al. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. , 1994, The Journal of biological chemistry.
[3] C. Lingwood,et al. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro , 1993, Infection and immunity.
[4] D. Newburg,et al. Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. , 1993, The Journal of infectious diseases.
[5] C. Lingwood,et al. Endothelial heterogeneity in Shiga toxin receptors and responses. , 1993, The Journal of biological chemistry.
[6] G. Tyrrell,et al. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs , 1993, The Journal of experimental medicine.
[7] H. König,et al. The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: Results of a Central European, multicentre study , 1993, Epidemiology and Infection.
[8] V. V. van Hinsbergh,et al. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. , 1992, Blood.
[9] V. Jay,et al. Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.
[10] C. Lingwood,et al. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. , 1992, Biochemistry.
[11] G. Tyrrell,et al. Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[12] Jasper Hii,et al. Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1 , 1991, Journal of clinical microbiology.
[13] H. Lior,et al. Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis , 1991, Journal of clinical microbiology.
[14] M. McKee,et al. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 , 1991, Infection and immunity.
[15] C. Lingwood,et al. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. , 1991, The Journal of biological chemistry.
[16] C. Gyles,et al. Reproduction of Edema Disease of Swine with Purified Shiga-like Toxin-II Variant , 1991, Veterinary pathology.
[17] J. Gariépy,et al. Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron. , 1990, The Biochemical journal.
[18] H R Smith,et al. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects. , 1990, Archives of disease in childhood.
[19] C. Lingwood,et al. Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides , 1990, Infection and immunity.
[20] J. Samuel,et al. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants , 1990, Infection and immunity.
[21] T. C. Roy,et al. Immunologic therapy for hemolytic-uremic syndrome. , 1989, The Journal of pediatrics.
[22] C. Lingwood,et al. Globotetraosylceramide is recognized by the pig edema disease toxin. , 1989, The Journal of biological chemistry.
[23] B. Dörken,et al. CD Antigens 1989 , 1989, International journal of cancer.
[24] T. Yutsudo,et al. Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2). , 1989, Microbial pathogenesis.
[25] S. Moseley,et al. Genotypic variation in pathogenic Escherichia coli O157:H7 isolated from patients in Washington, 1984-1987. , 1989, The Journal of infectious diseases.
[26] M. Karmali,et al. Infection by verocytotoxin-producing Escherichia coli , 1989, Clinical Microbiology Reviews.
[27] I. Wachsmuth,et al. SEROLOGICAL DIFFERENCES BETWEEN VEROCYTOTOXIN 2 AND SHIGA-LDCE TOXIN II , 1988, The Lancet.
[28] M. P. Jackson,et al. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine , 1988, Journal of bacteriology.
[29] L. Becker,et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. , 1988, Human pathology.
[30] J. H. Green,et al. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies , 1988, Infection and immunity.
[31] M. Petric,et al. Purification and characterization of verocytotoxin 2 , 1988 .
[32] J. Thompson,et al. Verotoxin production among porcine strains of Escherichia coli and its association with oedema disease. , 1987, Journal of medical microbiology.
[33] C. Lingwood,et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. , 1987, The Journal of biological chemistry.
[34] M. Petric,et al. Purification and biological properties of Escherichia coli verocytotoxin , 1987 .
[35] J. Brown,et al. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. , 1987, The Journal of biological chemistry.
[36] J. Friesen,et al. Cloning and expression of the genes specifying Shiga-like toxin production in Escherichia coli H19 , 1986, Journal of bacteriology.
[37] Peter D. Issitt,et al. Applied Blood Group Serology , 1985 .
[38] J. Wells,et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. , 1983, The New England journal of medicine.
[39] J. S. Fong,et al. Hemolytic-Uremic Syndrome: Current Concepts and Management , 1982 .
[40] G. D. Johnson,et al. A simple method of reducing the fading of immunofluorescence during microscopy. , 1981, Journal of immunological methods.
[41] E. Bremer,et al. P blood group regulation of glycosphingolipid levels in human erythrocytes. , 1979, The Journal of biological chemistry.
[42] M. David,et al. Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives. , 1977, Journal of lipid research.
[43] M. Naiki,et al. Abnormalities in the glycosphingolipid content of human Pk and p erythrocytes. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[44] T. Yamakawa,et al. Existence of glucosaminyl lactosyl ceramide (amino CTH-I) in human erythrocyte membranes as a possible precursor of blood group-active glycolipids. , 1976, Journal of biochemistry.
[45] M. Naiki,et al. An immunochemical study of the human blood group P1, P, and PK glycosphingolipid antigens. , 1975, Biochemistry.
[46] S. Cutillo. [Hemolytic-uremic syndrome]. , 1973, La Pediatria.
[47] B. Bull,et al. Red-blood-cell fragmentation in microangiopathic haemolytic anaemia: in-vitro studies. , 1967, Lancet.
[48] H. G. Rose,et al. IMPROVED PROCEDURE FOR THE EXTRACTION OF LIPIDS FROM HUMAN ERYTHROCYTES. , 1965, Journal of lipid research.
[49] C. Lingwood. Verotoxins and their glycolipid receptors. , 1993, Advances in lipid research.
[50] H. Karch,et al. Cloning and sequencing of a Shiga-like toxin II-related gene from Escherichia coli O157:H7 strain 7279. , 1992, Zentralblatt fur Bakteriologie : international journal of medical microbiology.
[51] C. Lingwood,et al. Verotoxin receptor glycolipid in human renal tissue. , 1989, Nephron.
[52] M. Roussey,et al. Le syndrome hémolytique et urémique de l'enfant , 1988 .
[53] A. Suzuki,et al. The P blood group system: recent progress in immunochemistry and genetics. , 1981, Seminars in hematology.
[54] Donckerwolcke Ra,et al. Haemolytic uraemic syndrome. , 1979, Paediatrician.